Laboratory testing is being reshaped by three converging forces: tighter regulation, faster product cycles, and digital-by-default evidence expectations. On the regulatory front, mandates are getting more prescriptive and measurable. In the United States, the EPA finalized the first national drinking-water standards for PFAS in April 2024, setting enforceable maximum contaminant levels (MCLG) of 4 parts per trillion for PFOA and 4 ppt for PFOS and establishing additional limits (including a hazard-index approach for mixtures), a step that is cascading upstream into materials, consumer products, and supply chains.
In the European Union, two major frameworks are already changing test menus: the restriction on intentionally added microplastics, effective October 2023, which brings particle identification and contamination-controlled workflows into scope for multiple product categories, and the Ecodesign for Sustainable Products Regulation (ESPR), effective July 2024, which underpins the Digital Product Passport (DPP)—driving demand for machine-readable evidence on material composition, durability, and recyclability.
In parallel, the FDA’s Modernization of Cosmetics Regulation Act (MoCRA) is now operational, with FDA guidance detailing who must register facilities and list products, what to submit, how and when to submit, and certain exemptions—raising the bar for auditable safety substantiation and data structures behind claims.
A lot is changing in consumer products, pharmaceuticals and biopharmaceuticals, environmental testing, metals and mining, food and beverage, medical devices, and cross-industry innovations.
If you are a third-party or contract testing lab, you need to know why the sector is shifting, the core trends reshaping test menus and methods, and the recent developments affecting operations, so you can take practical steps now to stay competitive.
Get a sector-by-sector look at the trends shaping laboratory testing in 2025 and beyond. Download the cross-industry playbook for insights into digital readiness and sustainability practices.
Non-Negotiable Patterns Across Sectors
Specialized methods and defensible data trails are moving from “nice-to-have” to non-negotiable. In pharma and biopharma, advanced therapy medicinal products (ATMPs) are pushing potency, identity, and chain-of-identity controls earlier in development, with European Medicines Agency (EMA) guidance emphasizing fit-for-purpose potency assays even at first-in-human.
In environmental programs, trace-level PFAS detection and the rise of non-target and suspect screening with high-resolution MS are helping labs flag unknowns and respond faster to emerging contaminants, provided sampling metadata and uncertainty are handled rigorously.
In metals and mining, the energy transition continues to reshape assay priorities: the International Energy Agency (IEA) reported that the lithium demand went up ~30% in 2023, with clean-energy technologies now a dominant demand driver across nickel, cobalt, graphite and other critical minerals; outlook scenarios still show multifold growth needs toward 2040 even as short-term prices fluctuate.
In medical devices, the FDA has finalized comprehensive cybersecurity guidance that ties software risk management, labeling, and documentation directly to quality-system expectations—pushing connected-device testing and digital traceability into the validation set.
Moreover, digital evidence is no longer a back-office concern. The ESPR’s DPP model anticipates product-level data that can be parsed by regulators, retailers, and recyclers; MoCRA and device cybersecurity guidance expect structured submissions and inspection-ready audit trails; and environmental programs require field-to-lab metadata that travels intact.
For contract, third-party, and in-house labs alike, that means laboratory information management system (LIMS)/electronic laboratory notebook (ELN) integration, machine-readable Certificates of Analysis (CoAs), version-controlled methods, and complete chains of custody are becoming the default.
What this Means for Labs
- Expect more method specificity and lower detection limits. PFAS MCLs, microplastics rules, and ATMP potency expectations are pushing labs toward trace-level analytics and well-documented validation.
- Treat evidence as a product. ESPR/DPP and MoCRA increase demand for machine-readable outputs, with method versions, uncertainties, and provenance packaged for downstream systems.
- Scale non-target capabilities where they matter. HRMS-based suspect/non-target screening is becoming a practical bridge between unknown risk and targeted quantitation—if sampled and reported with full metadata.
- Link field, lab, and quality systems. From environmental sampling to medical-device cybersecurity documentation, regulators are rewarding complete, traceable digital threads rather than isolated PDFs.
- Plan instrumentation and staffing for the energy transition. Despite commodity cycles, critical mineral demand linked to clean energy remains structurally higher across IEA scenarios, favoring labs that can reconcile fast field screening with bankable assays.
Are you a third-party laboratory looking to expand your business and stay relevant?
Contract Laboratory’s new and improved platform connects requesters worldwide to expert labs—safely, securely, and successfully.
Register your lab to join our network and showcase your lab, alongside industry bests.